Nocdurna Now Available for Nocturia Due to Nocturnal Polyuria

Ferring announced the availability of Nocdurna (desmopressin acetate) sublingual tablets for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least 2 times per night to void. It is the first sublingual tablet approved by the Food and Drug Administration (FDA) for this condition. 

Nocdurna, a vasopressin analog, was initially approved in June 2018 based on data from 3 double-blind, placebo-controlled, multicenter, randomized trials plus 1 open-label extension trial of up to 3 years in 220 patients aged ≥18 years. Nocdurna has specific sex-based dosing: women are prescribed 27.7mcg daily whereas men are prescribed 55.3mcg daily; it should be taken 1 hour before bedtime without water.

The antidiuretic effects of desmopressin are mediated by stimulation of vasopressin 2 (V2) receptors, thereby increasing water reabsorption in the kidneys, and reducing urine production. 

Related Articles

Nocdurna carries a Boxed Warning describing the risk of hyponatremia, which can be life-threatening if severe. Patients’ serum sodium levels should be normal prior to treatment start or resuming treatment. Serum sodium should be measured within 1 week and approximately 1 month after starting treatment and periodically during treatment; more frequent monitoring is required for elderly (≥65 years) and in patients at risk for hyponatremia.

Nocdurna is available as 27.7mcg and 55.3mcg sublingual tablets in 30-count cartons (3 blister packs with 10 tablets each).

For more information call (888) 337-7464 or visit